Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 14 % of short-term debt in 2024; threshold 65 %.
-
Busy address KBO
38 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
CIEL PHARMA from Brussel, company number BE0690987220, closed financial year 2024 with a result of € 15,001 after tax. For that financial year CIEL PHARMA recorded a gross margin of € 98,518 and equity of € 166,036. Compared with financial year 2023, the result moved from € 28,561 to € 15,001. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on November 14, 2025.
€ 166,036
▲ 10% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 15,001
▼ 47% vs 2023
Profit after tax over the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € 159,836.
People and assets in 2024
€ 48,186
▲ € 42,420 vs 2023
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2024
€ 765,789
▼ 8% vs 2023
€ 68,823 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 79,424
▲ 166% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 100,489
▲ 97% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 78,660 | € 122,584 | € 78,937 | € 98,518 | ▲ 25% |
| Profit after taxes | € 16,450 | € 48,200 | € 28,561 | € 15,001 | ▼ 47% |
| Equity | € 74,274 | € 122,474 | € 151,035 | € 166,036 | ▲ 10% |
| Total debts | € 1,188,665 | € 1,167,805 | € 1,617,724 | € 1,451,469 | ▼ 10% |
| Cash | - | € 15 | € 0 | - | |
| Land & buildings | € 474,664 | € 452,262 | € 438,872 | € 425,483 | ▼ 3% |
| Retained profit | € 68,074 | € 116,274 | € 144,835 | € 159,836 | ▲ 10% |
| Bank debt | € 945,675 | € 888,243 | € 828,156 | € 765,789 | ▼ 8% |
| Balance sheet total | € 1,262,939 | € 1,290,279 | € 1,768,759 | € 1,617,505 | ▼ 9% |
Key figures of CIEL PHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to CIEL PHARMA?
What happened at CIEL PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 15,001 (▼ 47% vs 2023). filed late Source: NBB ↗
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
In short
From € 16,450 profit in 2021 to € 15,001 profit in 2024.
Paid € 49,827 in corporate taxes since 2021.
Best year ever: 2022, with € 48,200 profit.
A new publication or filing at CIEL PHARMA? We notify you, reason included.
Follow CIEL PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind CIEL PHARMA is Ilias Atghaninti. Ilias Atghaninti is also behind DEVAPHAR.
Directors
According to the 2024 annual accounts
Establishments
Establishment units
Physical locations of this company
Louizalaan 200 box 8
1050 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 38 companies are registered at this address.
All companies at this address →Casa
BELGISCH-CHINESE ECONOMISCHE EN COMMERCIELE RAAD-BELGISCH-CHINESE KAMER VAN KOOPHANDEL
GOLDMANN ESTATES.EU
€ -6,931 gross margin · 2024
S.P.E.G.
€ 253,149 gross margin · 2024
DEVAPHAR same network
€ 262,261 gross margin · 2024
+33 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0690.987.220
- VAT number
- BE 0690.987.220
- Registered office
- Louizalaan 200 bus 8, 1050 Brussel
- Names & denominations
- CIEL PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 27 February 2018
- Peppol
- Active · Active since 7 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten